AirSculpt Technologies (AIRS) investor relations material

Market positioning and business model

• Differentiated, surgeon-led body contouring provider with proprietary minimally invasive technology and a scalable model.

• Operates 31 centers, employs over 350 people, and performs over 12,000 procedures annually.

• Achieves approximately 60% gross margin and collects 100% upfront cash payments.

• De novo centers reach profitability within months, with mature centers requiring minimal capex for growth.

• Consistent revenue per case of $12,000–$13,000, supported by ongoing innovation and expanded service offerings.

Financial performance and outlook

• 2026 revenue guidance is $151M–$157M, with adjusted EBITDA guidance of $12M–$14M.

• Gross margin remains strong at around 60%.

• Same-center sales improved from -23% in 1H25 to approximately flat year-to-date, with case volumes up 1%.

• Returned to positive same-center sales in February 2026, with sequential acceleration expected through 2025.

• Adjusted EBITDA margin expected to stabilize at 8.2%–8.4% in 2026.

Growth strategy and market opportunity

• Three main growth levers: enhanced marketing, expanded GLP-1-related services, and de novo center expansion.

• Enhanced marketing focuses on high-intent audiences, influencer engagement, and new PR/marketing agencies.

• GLP-1 drugs drive a structural shift in demand, with a projected 400% increase in users by 2030.

• Expanded services include skin tightening, fat transfer, and new offerings for post-GLP-1 patients.

• Significant white space for de novo expansion, with potential for 200–300 additional U.S./Canada centers and 150–250 international centers.